Oncology Voice Network
Join the Oncology Voice Network. Join for Free
Season 2, Episode 18: Turning the Page with Chadi Nabhan

Season 2, Episode 18: Turning the Page with Chadi Nabhan

  • Sep 15th 2025
  • 23 mins
  • The Pharmaverse Podcast

Share This Article

Join Michael Pietrack on the Pharmaverse Podcast as he sits down with Dr. Chadi Nabhan, MD – CMO and Head of Strategy at RyghtAI, hematologist, oncologist, author, and podcast host – to explore the future of clinical trials, AI innovation, and leadership in healthcare.

In this episode, Dr. Nabhan shares:

✔️How RyghtAI uses AI digital twins to speed up clinical trials and reduce costs.

✔️The process of matching clinical trial protocols to the best sites worldwide.

✔️Lessons learned from mentorship, leadership, and his medical career.

✔️Insights from his books, including Toxic Exposure and The Cancer Journey.

✔️Strategies for balancing executive roles, healthcare innovation, and family life.

Whether you’re interested in AI in healthcare, clinical research, or leadership in biotech, this conversation is full of practical advice and inspiring stories. 

Watch on YouTube

Related Topics

Explore the Ecosystem

Meet Our Innovation Partners

You May Also Like

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Jun 18th • 30 mins • read
Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Dec 20th • 15 mins • read
Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Dec 1st • 10 mins • read
Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Jan 7th • 8 mins • read
Article
Value assessment frameworks in oncology: championing concordance through shared standards
OVN Avatar M. Bertagnolli and J. Tabernero

Value assessment frameworks in oncology: championing concordance through shared standards

Feb 18th • 1 min • read
Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Sep 21st • 3 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN